Cervical Cancer: Awareness and Equity

CE / CME

Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Cervical Cancer

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: June 26, 2023

Expiration: June 25, 2024

Shannon N. Westin
Shannon N. Westin, MD, MPH, FASCO

Activity

Progress
1
Course Completed

Equity in Cervical Cancer

Despite exciting advances in the field of gynecologic oncology, underrepresented racial and ethnic minority patients disproportionally face barriers to optimal/equitable care for cervical cancer. Moreover, data also suggest that many healthcare professionals (HCPs) caring for patients with cervical cancer are unaware of the disparities in their field. Recognition—and raising awareness—of factors contributing to inequities is an important first step in improving care for all patients with cervical cancer to help overcome these barriers. 

In this module, Shannon N. Westin, MD, MPH, reviews and discusses key factors leading to inequitable care for cervical cancer and proposes strategies to overcome them with guideline-concordant care. This module is part of a larger educational program tasked with raising awareness and sharing experts’ strategies for improving outcomes for all patients with gynecologic cancers. 

Please note that the slide thumbnails in this activity link to PowerPoint slidesets that also can be found here, each focused on the specific gynecologic topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity. 

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Poll

If you are a HCP providing patient care, how many patients with cervical cancer do you see in a typical month?

Presurvey

Dorian is a 37-year-old patient with a history of advanced cervical cancer. She previously received treatment with surgery plus chemoradiation. She recently presented with liver recurrence and residual peripheral neuropathy from previous chemoradiation. IHC testing performed on her liver biopsy demonstrated a PD-L1 combined positive score of 2 (positive) and was found to have HER2 mutation by NGS.

Based on these presentation characteristics, which second-line treatment options would be most appropriate for her?

To which of the following specialists should you send your patients receiving tisotumab vedotin for recurrent cervical cancer to implement the recommended adverse event (AE) prevention and mitigation strategies for this agent?